|Bid||1.5700 x 73500|
|Ask||1.5800 x 199500|
|Day's Range||1.5700 - 1.6300|
|52 Week Range||1.3800 - 4.2900|
|PE Ratio (TTM)||10.64|
|Earnings Date||Sep 20, 2017 - Sep 25, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.04|
Rite Aid Corporation today announced that it has commenced an offer to purchase for cash up to $700,000,000 of certain of its outstanding indebtedness, consisting of its 6.75% Senior Notes due 2021 and 6.125% Senior Notes due 2023 , with a portion of the net cash proceeds received from its previously announced sale to Walgreens Boots Alliance, Inc.
Rite Aid Corporation (RAD) announced today that naloxone, a medication that can be used to reverse the effects of an opioid overdose, is available at each of the more than 2,500 Rite Aid pharmacies in the United States and can be dispensed without a prescription, subject to state regulations. “The opioid epidemic has reached epic proportions and it is an issue that demands not only our attention but also our continued action to help reduce the rise in opioid deaths,” said Jocelyn Konrad, Rite Aid executive vice president of pharmacy. “For the past two years, we’ve worked with state and federal lawmakers to increase access to this life-saving medication.
Rite Aid’s (RAD) management provided guidance for fiscal 2019 in its fiscal 4Q18 report. Management believes the company will benefit from generic drug purchasing efficiencies, a more stable reimbursement rate environment, Walgreens’s deal-related TSA (Transportation Security Administration) fees, and the company’s ongoing initiatives in fiscal 2019.
As we saw in the previous part of this series, Rite Aid (RAD) reported an 8.6% YoY (year-over-year) decline in its fiscal 4Q18 revenues from continuing operations to $5.4 billion. Its Retail Pharmacy segment, which includes prescription drugs, health and beauty products, and personal care items, saw its revenue fall 10.1% to $4 billion. Same-store sales from continuing operations fell 1.7% YoY during the quarter, driven by a 2.3% decline in pharmacy sales and a 0.6% fall in front-end sales.
Rite Aid (RAD) reported its fiscal 4Q18 results after the market closed on Thursday, April 12, 2018. Its top line fell 8.6% YoY (year-over-year) to $5.4 billion, missing the average consensus expectation by $180 million.
CVS (CVS), which is an American retail pharmacy and healthcare company, was the S&P 500’s second-highest performer on April 16. After gaining for three consecutive trading days, CVS opened higher on Monday and surged to four-week high price levels.
On Thursday, April 12, 2018, Rite Aid (RAD) reported its results for fiscal 4Q18 and fiscal 2018. The results relate to the three-month and 12-month period that ended March 3, 2018.
NEW YORK, NY / ACCESSWIRE / April 17, 2018 / Shares of Walgreens and Rite Aid saw gains on Monday after reports emerged that Amazon has shelved its plans to sell prescription drugs to doctors and hospitals. ...
NEW YORK, April 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Rite Aid (RAD) reports better-than-expected bottom-line results for fourth-quarter fiscal 2018, while sales disappoint. Improvement in reimbursement rates aid results.
Some Rite Aid Corp. shareholders plan to oppose a merger with grocer Albertsons Cos. that they believe undervalues the struggling pharmacy chain. Rite Aid’s shares have fallen about 20% since the companies said they would merge on Feb. 20, a sign of deepening investor disapproval. Albertsons is closely held.
Rite Aid Corp. said Thursday it had net income of $767 million, or 73 cents a share, in the fourth quarter, after a loss of $21 million, or 2 cents a share, in the year-earlier period. The company's loss ...
Rite Aid Corporation today reported operating results for its fourth quarter and fiscal year ended March 3, 2018.
Rite Aid’s stock has plunged around 18% this year after falling 76% last year. Rite Aid is now sitting 202% below its 52-week high price. The delay and eventual termination of its initial deal with Walgreens’s (WBA) announced in October 2015 hurt the company’s stock price last year.
Rite Aid (RAD) is projected to post a loss of ten cents per share during its 4Q18 earnings report on April 12. Rite Aid has witnessed a deterioration in its profitability over the years. Rite Aid has weaker margins than the other two major drugstore chains.
Rite Aid (RAD), which will report its 4Q18 results on April 12, is projected to report a 34.8% YoY (year-over-year) decline in total sales to $5.6 billion. During the first nine months of the year, Rite Aid’s total sales fell 4.5% YoY to $23.2 billion. It missed consensus expectations in two of the three reported quarters.
Pennsylvania–based Rite Aid (RAD) is slated to release fiscal 4Q18 results on Thursday, April 12, 2018. The company is projected to report earnings per share of -$0.10 as compared to last year’s $0.00 per share. Total revenue is expected to fall 34.8% to $5.6 billion.
Markets head into the week ahead, battered by trade war fears, and the selling pressure could continue if there are no signs of a breakthrough.
Albertsons Companies Inc. filed Friday to withdraw its plan for an initial public offering, because of its deal to merge with Rite Aid Corp. , which was announced in February. The food and drug retailer ...
Rite Aid Corporation said today that it will release financial results for its Fiscal 2018 Fourth Quarter, which ended March 3, 2018, on Thursday, April 12, 2018. The company will hold an analyst call at 8:30 a.m.
NEW YORK, NY / ACCESSWIRE / April 2, 2018 / Shares of Rite Aid saw gains on Thursday as it was announced this week that the company received U.S. regulatory approval and is inching towards completing its ...
LONDON, UK / ACCESSWIRE / April 02, 2018 / Active-Investors.com has just released a free research report on Rite Aid Corp. (NYSE: RAD ). If you want access to this report all you need to do is sign up ...
Rite Aid Corporation today announced the results of its previously announced offer to purchase up to $900,000,000 of its outstanding 9.25% Senior Notes due 2020 , 6.75% Senior Notes due 2021 and 6.125% Senior Notes due 2023 for cash at a price equal to 100% of the principal amount of the Notes, equivalent to $1,000 per $1,000 principal amount of Notes, plus accrued and unpaid interest, if any, for ...
As we saw in the previous part of this series, Walgreens Boots Alliance (WBA) reported its fiscal 2Q18 results on March 28, 2018. The company’s top line increased 12% YoY (year-over-year) to $33 billion. Stefano Pessina, executive vice chairman and CEO of Walgreens, said, “Our growth strategy of increasing and consolidating volume, differentiating ourselves through value and quality of service, and controlling costs is bearing fruit across our businesses.